Core components by DAPSA states with secukinumab or placebo at Wk 16
| Mean ± SD | SJC (66) | TJC (68) | PtGA (cm) | PP (cm) | CRP (mg/dl) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 300mg/150mg | PBO | 300mg/150mg | PBO | 300mg/150mg | PBO | 300mg/150mg | PBO | 300mg/150mg | PBO | |
| REM* | 0.4±0.7/0.2±0.4 | 1.0±1.4 | 0.2±0.4/0.3±0.5 | 0.5±1.0 | 0.6±0.5/0.6±0.5 | 0.6±0.6 | 0.7±0.7/0.7±0.4 | 0.8±0.6 | 0.3±0.3/0.5±0.4 | 0.2±0.2 |
| LDA^ | 1.7±2.3/1.4±1.6 | 1.6±2.0 | 2.5±1.9/1.8±2.2 | 2.3±2.7 | 2.3±1.6/2.1±1.2 | 2.3±1.8 | 2.3±1.3/2.3±1.3 | 2.6±1.8 | 0.4±0.4/0.4±0.7 | 0.2±0.3 |
| MDA# | 4.5±3.8/4.9±3.0 | 4.9±3.4 | 6.0±4.1/7.0±2.8 | 7.5±4.1 | 3.8±2.3/3.9±1.9 | 3.9±1.8 | 4.1±2.0/3.8±1.8 | 4.5±1.8 | 0.4±0.4/0.9±1.0 | 0.7±1.2 |
| HDA$ | 10.7±7.5/14.4±11.1 | 10.4±7.2 | 24.6±12.4/29.2±19.0 | 26.6±15.2 | 4.9±1.7/5.6±2.0 | 5.9±1.8 | 5.2±1.9/5.6±1.8 | 6.1±1.5 | 0.4±0.4/0.6±0.7 | 1.2±1.7 |
*n=14 (300mg), 10 (150mg) and 4 (PBO); ^n=27 (300mg), 34 (150mg) and 12 (PBO); #n=26 (300mg), 24 (150mg) and 22 (PBO); $n=30 (300mg), 32 (150mg) and 49 (PBO).